Targeting Inflammatory Responses to Streptococcus pneumoniae

New Horizons in Translational Medicine

Volumn 2, Issue 6-7, 2015, Pages 167-174

  Periselneris, Jimstan ^a   José, Ricardo J ^a   Brown, Jeremy ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Inflammation; Meningitis; Pneumonia; Streptococcus pneumonia

Indexed keywords

ABSENT IN MELANOMA 2 PROTEIN; ALPHA INTERFERON; AMPICILLIN; AZITHROMYCIN; BETA INTERFERON; BETA LACTAM ANTIBIOTIC; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CLINDAMYCIN; CRYOPYRIN; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROLIDE; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MOXIFLOXACIN; PREDNISOLONE; PROTEIN; RANTES; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VORAPAXAR;

ACUTE PHASE RESPONSE; BACTERIAL CLEARANCE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOMODULATION; INFLAMMATION; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MORTALITY; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TISSUE INJURY;

EID: 84959148985     PISSN: None     EISSN: 23075023     Source Type: Journal    
DOI: 10.1016/j.nhtm.2015.09.002     Document Type: Review

References (108)

1. Albiger B., Dahlberg S., Sandgren A., Wartha F., Beiter K., Katsuragi H., Akira S., Normark S., Henriques-Normark B. Toll-like receptor 9 acts at an early stage in host defence against pneumococcal infection. Cell. Microbiol. 2007, 9(3):633-644.
2. Albiger B., Sandgren A., Katsuragi H., Meyer-Hoffert U., Beiter K., Wartha F., Hornef M., Normark S., Normark B.H. Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice. Cell. Microbiol. 2005, 7(11):1603-1615.
3. Arredouani M., Yang Z., Ning Y., Qin G., Soininen R., Tryggvason K., Kobzik L. The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. J. Exp. Med. 2004, 200(2):267-272.
4. Asadi L., Sligl W.I., Eurich D.T., Colmers I.N., Tjosvold L., Marrie T.J., Majumdar S.R. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin. Infect. Dis. 2012, 55(3):371-380.
5. Baddour L.M., Yu V.L., Klugman K.P., Feldman C., Ortqvist A., Rello J., Morris A.J., Luna C.M., Snydman D.R., Ko W.C., Chedid M.B., Hui D.S., Andremont A., Chiou C.C., International Pneumococcal Study G. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med. 2004, 170(4):440-444.
6. Beisswenger C., Honecker A., Kamyschnikow A., Bischoff M., Tschernig T., Bals R. Moxifloxacin modulates inflammation during murine pneumonia. Respir. Res. 2014, 15:82.
7. Blum C.A., Nigro N., Briel M., Schuetz P., Ullmer E., Suter-Widmer I., Winzeler B., Bingisser R., Elsaesser H., Drozdov D., Arici B., Urwyler S.A., Refardt J., Tarr P., Wirz S., Thomann R., Baumgartner C., Duplain H., Burki D., Zimmerli W., Rodondi N., Mueller B., Christ-Crain M. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015, 385(9977):1511-1518.
8. Branger J., Knapp S., Weijer S., Leemans J.C., Pater J.M., Speelman P., Florquin S., van der Poll T. Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice. Infect. Immun. 2004, 72(2):788-794.
9. Brouwer M.C., McIntyre P., Prasad K., van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev. 2015, 9:CD004405.
10. Brown R.B., Iannini P., Gross P., Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003, 123(5):1503-1511.
11. Bu D.X., Griffin G., Lichtman A.H. Mechanisms for the anti-inflammatory effects of statins. Curr. Opin. Lipidol. 2011, 22(3):165-170.
12. Calbo E., Garau J. Of mice and men: innate immunity in pneumococcal pneumonia. Int. J. Antimicrob. Agents 2010, 35(2):107-113.
13. Camberlein E., Cohen J.M., Jose R., Hyams C.J., Callard R., Chimalapati S., Yuste J., Edwards L.A., Marshall H., van Rooijen N., Noursadeghi M., Brown J.S. Importance of bacterial replication and alveolar macrophage-independent clearance mechanisms during early lung infection with Streptococcus pneumoniae. Infect. Immun. 2015, 83(3):1181-1189.
14. Cao J., Wang D., Xu F., Gong Y., Wang H., Song Z., Li D., Zhang H., Zhang L., Xia Y., Xu H., Lai X., Lin S., Zhang X., Ren G., Dai Y., Yin Y. Activation of IL-27 signalling promotes development of postinfluenza pneumococcal pneumonia. EMBO Mol. Med. 2014, 6(1):120-140.
15. Choi G., Hofstra J.J., Roelofs J.J., Rijneveld A.W., Bresser P., van der Zee J.S., Florquin S., van der Poll T., Levi M., Schultz M.J. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit. Care Med. 2008, 36(1):204-210.
16. Clarke T.B., Francella N., Huegel A., Weiser J.N. Invasive bacterial pathogens exploit TLR-mediated downregulation of tight junction components to facilitate translocation across the epithelium. Cell Host Microbe 2011, 9(5):404-414.
17. Coutinho A., Moller G. B cell mitogenic properties of thymus-independent antigens. Nat.: New Biol. 1973, 245(140):12-14.
18. Davis K.M., Nakamura S., Weiser J.N. Nod2 sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. J. Clin. Investig. 2011, 121(9):3666-3676.
19. de Gans J., van de Beek D. Dexamethasone in adults with bacterial meningitis. New Engl. J. Med. 2002, 347(20):1549-1556.
20. Dessing M.C., Hirst R.A., de Vos A.F., van der Poll T. Role of Toll-like receptors 2 and 4 in pulmonary inflammation and injury induced by pneumolysin in mice. PloS One 2009, 4(11):e7993.
21. Dixon B., Schultz M.J., Hofstra J.J., Campbell D.J., Santamaria J.D. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit. Care 2010, 14(5):445.
22. Dockrell D.H., Marriott H.M., Prince L.R., Ridger V.C., Ince P.G., Hellewell P.G., Whyte M.K. Alveolar macrophage apoptosis contributes to pneumococcal clearance in a resolving model of pulmonary infection. J. Immunol. 2003, 171(10):5380-5388.
23. dos Santos G., Kutuzov M.A., Ridge K.M. The inflammasome in lung diseases. Am. J. Physiol. - Lung Cell. Mole. Physiol. 2012, 303(8):L627-L633.
24. Douglas I., Evans S., Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011, 342:d1642.
25. Ely E.W., Laterre P.F., Angus D.C., Helterbrand J.D., Levy H., Dhainaut J.F., Vincent J.L., Macias W.L., Bernard G.R., Investigators P. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit. Care Med. 2003, 31(1):12-19.
26. Fang R., Tsuchiya K., Kawamura I., Shen Y., Hara H., Sakai S., Yamamoto T., Fernandes-Alnemri T., Yang R., Hernandez-Cuellar E., Dewamitta S.R., Xu Y., Qu H., Alnemri E.S., Mitsuyama M. Critical roles of ASC inflammasomes in caspase-1 activation and host innate resistance to Streptococcus pneumoniae infection. J. Immunol. 2011, 187(9):4890-4899.
27. Garcha D.S., Thurston S.J., Patel A.R., Mackay A.J., Goldring J.J., Donaldson G.C., McHugh T.D., Wedzicha J.A. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012, 67(12):1075-1080.
28. Geijtenbeek T.B., Torensma R., van Vliet S.J., van Duijnhoven G.C., Adema G.J., van Kooyk Y., Figdor C.G. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000, 100(5):575-585.
29. Geldhoff M., Mook-Kanamori B.B., Brouwer M.C., Troost D., Leemans J.C., Flavell R.A., Van der Ende A., Van der Poll T., Van de Beek D. Inflammasome activation mediates inflammation and outcome in humans and mice with pneumococcal meningitis. BMC Infect. Dis. 2013, 13(1):358.
30. Geldhoff M., Mook-Kanamori B.B., Brouwer M.C., Valls Seron M., Baas F., van der Ende A., van de Beek D. Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis. Immunogenetics 2013, 65(1):9-16.
31. Gerber J., Bottcher T., Hahn M., Siemer A., Bunkowski S., Nau R. Increased mortality and spatial memory deficits in TNF-alpha-deficient mice in ceftriaxone-treated experimental pneumococcal meningitis. Neurobiol. Dis. 2004, 16(1):133-138.
32. Ghoneim H.E., McCullers J.A. Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice. J. Infect. Dis. 2014, 209(9):1459-1468.
33. Gwyer Findlay E., Hussell T. Macrophage-mediated inflammation and disease: a focus on the lung. Mediat. Inflamm. 2012, 2012:140937.
34. Herbold W., Maus R., Hahn I., Ding N., Srivastava M., Christman J.W., Mack M., Reutershan J., Briles D.E., Paton J.C., Winter C., Welte T., Maus U.A. Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. Infect. Immun. 2010, 78(6):2620-2630.
35. Hoegen T., Tremel N., Klein M., Angele B., Wagner H., Kirschning C., Pfister H.W., Fontana A., Hammerschmidt S., Koedel U. "The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release. J. Immunol. 2011, 187(10):5440-5451.
36. Hofstra J.J., Cornet A.D., de Rooy B.F., Vlaar A.P., van der Poll T., Levi M., Zaat S.A., Schultz M.J. Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit. Care 2009, 13(5):R145.
37. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., Fitzgerald K.A., Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008, 9(8):847-856.
38. Hyams C., Camberlein E., Cohen J.M., Bax K., Brown J.S. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect. Immun. 2010, 78(2):704-715.
39. Hyams C., Trzcinski K., Camberlein E., Weinberger D.M., Chimalapati S., Noursadeghi M., Lipsitch M., Brown J.S. Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b. Infect. Immun. 2013, 81(1):354-363.
40. Jones M.R., Simms B.T., Lupa M.M., Kogan M.S., Mizgerd J.P. Lung NF-kappaB activation and neutrophil recruitment require IL-1 and TNF receptor signaling during pneumococcal pneumonia. J. Immunol. 2005, 175(11):7530-7535.
41. Jose R.J., Williams A.E., Chambers R.C. Proteinase-activated receptors in fibroproliferative lung disease. Thorax 2014, 69(2):190-192.
42. Jose R.J., Williams A.E., Mercer P.F., Sulikowski M.G., Brown J.S., Chambers R.C. Regulation of Neutrophilic Inflammation by Proteinase-Activated Receptor 1 during Bacterial Pulmonary Infection. J. Immunol. 2015, 194(12):6024-6034.
43. Karlstrom A., Heston S.M., Boyd K.L., Tuomanen E.I., McCullers J.A. Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J. Infect. Dis. 2011, 204(9):1358-1366.
44. Kasanmoentalib E.S., Valls Seron M., Morgan B.P., Brouwer M.C., van de Beek D. Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial. J. Neuroinflammation 2015, 12:149.
45. Kim B.J., Lee S., Berg R.E., Simecka J.W., Jones H.P. Interleukin-23 (IL-23) deficiency disrupts Th17 and Th1-related defenses against Streptococcus pneumoniae infection. Cytokine 2013, 64(1):375-381.
46. Knippenberg S., Ueberberg B., Maus R., Bohling J., Ding N., Tort Tarres M., Hoymann H.G., Jonigk D., Izykowski N., Paton J.C., Ogunniyi A.D., Lindig S., Bauer M., Welte T., Seeger W., Guenther A., Sisson T.H., Gauldie J., Kolb M., Maus U.A. Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin. Thorax 2015, 70(7):636-646.
47. Koedel U., Rupprecht T., Angele B., Heesemann J., Wagner H., Pfister H.W., Kirschning C.J. MyD88 is required for mounting a robust host immune response to Streptococcus pneumoniae in the CNS. Brain: J. Neurol. 2004, 127(6):1437-1445.
48. Koppel E.A., Wieland C.W., van den Berg V.C., Litjens M., Florquin S., van Kooyk Y., van der Poll T., Geijtenbeek T.B. Specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) expressed by marginal zone macrophages is essential for defense against pulmonary Streptococcus pneumoniae infection. Eur. J. Immunol. 2005, 35(10):2962-2969.
49. Laterre P.F., Garber G., Levy H., Wunderink R., Kinasewitz G.T., Sollet J.P., Maki D.G., Bates B., Yan S.C., Dhainaut J.F. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit. Care Med. 2005, 33(5):952-961.
50. LeMessurier K.S., Hacker H., Chi L., Tuomanen E., Redecke V. Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathog. 2013, 9(11):e1003727.
51. Li W., Moltedo B., Moran T.M. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J. Virol. 2012, 86(22):12304-12312.
52. Liu X., Chauhan V.S., Young A.B., Marriott I. "NOD2 mediates inflammatory responses of primary murine glia to Streptococcus pneumoniae. Glia 2010, 58(7):839-847.
53. Majumdar S.R., McAlister F.A., Eurich D.T., Padwal R.S., Marrie T.J. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006, 333(7576):999.
54. Malley R., Henneke P., Morse S.C., Cieslewicz M.J., Lipsitch M., Thompson C.M., Kurt-Jones E., Paton J.C., Wessels M.R., Golenbock D.T. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(4):1966-1971.
55. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(13):4848-4853.
56. Marriott H.M., Gascoyne K.A., Gowda R., Geary I., Nicklin M.J., Iannelli F., Pozzi G., Mitchell T.J., Whyte M.K., Sabroe I., Dockrell D.H. Interleukin-1beta regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages. Infect. Immun. 2012, 80(3):1140-1149.
57. Maus U.A., Srivastava M., Paton J.C., Mack M., Everhart M.B., Blackwell T.S., Christman J.W., Schlondorff D., Seeger W., Lohmeyer J. Pneumolysin-induced lung injury is independent of leukocyte trafficking into the alveolar space. J. Immunol. 2004, 173(2):1307-1312.
58. McNeela E.A., Burke A., Neill D.R., Baxter C., Fernandes V.E., Ferreira D., Smeaton S., El-Rachkidy R., McLoughlin R.M., Mori A., Moran B., Fitzgerald K.A., Tschopp J., Petrilli V., Andrew P.W., Kadioglu A., Lavelle E.C. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog. 2010, 6(11):e1001191.
59. Meijvis S.C., Hardeman H., Remmelts H.H., Heijligenberg R., Rijkers G.T., van Velzen-Blad H., Voorn G.P., van de Garde E.M., Endeman H., Grutters J.C., Bos W.J., Biesma D.H. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 377(9782):2023-2030.
60. Mitchell A.J., Yau B., McQuillan J.A., Ball H.J., Too L.K., Abtin A., Hertzog P., Leib S.L., Jones C.A., Gerega S.K., Weninger W., Hunt N.H. Inflammasome-dependent IFN-gamma drives pathogenesis in Streptococcus pneumoniae meningitis. J. Immunol. 2012, 189(10):4970-4980.
61. Musher D.M., Rueda A.M., Kaka A.S., Mapara S.M. The association between pneumococcal pneumonia and acute cardiac events. Clin. Infect. Dis. 2007, 45(2):158-165.
62. Nakada T.A., Russell J.A., Boyd J.H., Walley K.R. IL17A genetic variation is associated with altered susceptibility to Gram-positive infection and mortality of severe sepsis. Crit. Care 2011, 15(5):R254.
63. Naucler P., Darenberg J., Morfeldt E., Ortqvist A., Henriques Normark B. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013, 68(6):571-579.
64. Neill D.R., Fernandes V.E., Wisby L., Haynes A.R., Ferreira D.M., Laher A., Strickland N., Gordon S.B., Denny P., Kadioglu A., Andrew P.W. T regulatory cells control susceptibility to invasive pneumococcal pneumonia in mice. PLoS Pathog. 2012, 8(4):e1002660.
65. OBrien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., Lee E., Mulholland K., Levine O.S., Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
66. Olliver M., Hiew J., Mellroth P., Henriques-Normark B., Bergman P. Human monocytes promote Th1 and Th17 responses to Streptococcus pneumoniae. Infect. Immun. 2011, 79(10):4210-4217.
67. Opitz B., Puschel A., Schmeck B., Hocke A.C., Rosseau S., Hammerschmidt S., Schumann R.R., Suttorp N., Hippenstiel S. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J. Biol. Chem. 2004, 279(35):36426-36432.
68. Palaniappan R., Singh S., Singh U.P., Singh R., Ades E.W., Briles D.E., Hollingshead S.K., Royal W., Sampson J.S., Stiles J.K., Taub D.D., Lillard J.W. CCL5 modulates pneumococcal immunity and carriage. J. Immunol. 2006, 176(4):2346-2356.
69. Parker D., Martin F.J., Soong G., Harfenist B.S., Aguilar J.L., Ratner A.J., Fitzgerald K.A., Schindler C., Prince A. Streptococcus pneumoniae DNA initiates type I interferon signaling in the respiratory tract. mBio 2011, 2(3):e00016-00011.
70. Parker D., Prince A. Type I interferon response to extracellular bacteria in the airway epithelium. Trends Immunol. 2011, 32(12):582-588.
71. Penaloza H.F., Nieto P.A., Munoz-Durango N., Salazar-Echegarai F.J., Torres J., Parga M.J., Alvarez-Lobos M., Riedel C.A., Kalergis A.M., Bueno S.M. Interleukin-10 plays a key role in the modulation of neutrophils recruitment and lung inflammation during infection by Streptococcus pneumoniae. Immunology 2015, 146(1):100-112.
72. Postma D.F., van Werkhoven C.H., van Elden L.J., Thijsen S.F., Hoepelman A.I., Kluytmans J.A., Boersma W.G., Compaijen C.J., van der Wall E., Prins J.M., Oosterheert J.J., Bonten M.J., Group C.-S.S. "Antibiotic treatment strategies for community-acquired pneumonia in adults. N. Engl. J. Med. 2015, 372(14):1312-1323.
73. Quinton L.J., Jones M.R., Robson B.E., Mizgerd J.P. Mechanisms of the hepatic acute-phase response during bacterial pneumonia. Infect. Immun. 2009, 77(6):2417-2426.
74. Restrepo M.I., Mortensen E.M., Waterer G.W., Wunderink R.G., Coalson J.J., Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur. Respir. J. 2009, 33(1):153-159.
75. Rodrigo C., McKeever T.M., Woodhead M., Lim W.S., British Thoracic S. Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 2013, 68(5):493-495.
76. Schouten M., vant Veer C., Roelofs J.J., Gerlitz B., Grinnell B.W., Levi M., van der Poll T. Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia. Thromb. Haemost. 2011, 106(6):1189-1196.
77. Seyoum B., Yano M., Pirofski L.A. The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response. Vaccine 2011, 29(45):8002-8011.
78. Snijders D., Daniels J.M., de Graaff C.S., van der Werf T.S., Boersma W.G. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am. J. Respir. Crit. Care Med. 2010, 181(9):975-982.
79. Sun K., Salmon S.L., Lotz S.A., Metzger D.W. Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect. Immun. 2007, 75(3):1196-1202.
80. Takashima K., Tateda K., Matsumoto T., Iizawa Y., Nakao M., Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 1997, 65(1):257-260.
81. Taut K., Winter C., Briles D.E., Paton J.C., Christman J.W., Maus R., Baumann R., Welte T., Maus U.A. Macrophage Turnover Kinetics in the Lungs of Mice Infected with Streptococcus pneumoniae. Am. J. Respir. Cell. Mol. Biol. 2008, 38(1):105-113.
82. Tessmer A., Welte T., Martus P., Schnoor M., Marre R., Suttorp N. Impact of intravenous-lactam/macrolide versus-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J. Antimicrob. Chemother. 2009, 63(5):1025-1033.
83. Tomankova T., Kriegova E., Liu M. Chemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte trafficking. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015, 308(7):L603-L618.
84. Tomlinson G., Chimalapati S., Pollard T., Lapp T., Cohen J., Camberlein E., Stafford S., Periselneris J., Aldridge C., Vollmer W., Picard C., Casanova J.L., Noursadeghi M., Brown J. TLR-Mediated Inflammatory Responses to Streptococcus pneumoniae are highly dependent on surface expression of bacterial lipoproteins. J. Immunol. 2014, 193(7):3736-3745.
85. Torres A., Sibila O., Ferrer M., Polverino E., Menendez R., Mensa J., Gabarrus A., Sellares J., Restrepo M.I., Anzueto A., Niederman M.S., Agusti C. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015, 313(7):677-686.
86. Van Den Boogaard F.E., Brands X., Schultz M.J., Levi M., Roelofs J.J., Vant Veer C., Van Der Poll T. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J. Thromb. Haemost. 2011, 9(1):122-132.
87. van den Boogaard F.E., Hofstra J.J., vant Veer C., Levi M.M., Roelofs J.J., van der Poll T., Schultz M.J. Feasibility and safety of local treatment with recombinant human tissue factor pathway inhibitor in a rat model of Streptococcus pneumoniae Pneumonia. PLoS One 2015, 10(5):e0127261.
88. van der Poll T., Keogh C.V., Buurman W.A., Lowry S.F. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 1997, 155(2):603-608.
89. van der Poll T., Keogh C.V., Guirao X., Buurman W.A., Kopf M., Lowry S.F. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J. Infect. Dis. 1997, 176(2):439-444.
90. van Der Poll T., Marchant A., van Deventer S.J. The role of interleukin-10 in the pathogenesis of bacterial infection: Clinical microbiology and infection: the official publication of the European Society. Clin. Microbiol. Infect. Dis. 1997, 3(6):605-607.
91. Vollmer W., Tomasz A. Peptidoglycan N-acetylglucosamine deacetylase, a putative virulence factor in Streptococcus pneumoniae. Infect. Immun. 2002, 70(12):7176-7178.
92. von Bernuth H., Picard C., Jin Z., Pankla R., Xiao H., Ku C.L., Chrabieh M., Mustapha I.B., Ghandil P., Camcioglu Y., Vasconcelos J., Sirvent N., Guedes M., Vitor A.B., Herrero-Mata M.J., Arostegui J.I., Rodrigo C., Alsina L., Ruiz-Ortiz E., Juan M., Fortuny C., Yague J., Anton J., Pascal M., Chang H.H., Janniere L., Rose Y., Garty B.Z., Chapel H., Issekutz A., Marodi L., Rodriguez-Gallego C., Banchereau J., Abel L., Li X., Chaussabel D., Puel A., Casanova J.L. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008, 321(5889):691-696.
93. Walker C.L., Rudan I., Liu L., Nair H., Theodoratou E., Bhutta Z.A., OBrien K.L., Campbell H., Black R.E. Global burden of childhood pneumonia and diarrhoea. Lancet 2013, 381(9875):1405-1416.
94. Wang E., Bergeron Y., Bergeron M.G. Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia. J. Antimicrob. Chemother. 2005, 55(5):721-726.
95. Weber S.E., Tian H., Pirofski L.A. CD8+ cells enhance resistance to pulmonary serotype 3 Streptococcus pneumoniae infection in mice. J. Immunol. 2011, 186(1):432-442.
96. Weiss T., Shalit I., Blau H., Werber S., Halperin D., Levitov A., Fabian I. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob. Agents Chemother. 2004, 48(6):1974-1982.
97. Williams A.E., Jose R.J., Brown J.S., Chambers R.C. Enhanced inflammation in aged mice following infection with Streptococcus pneumoniae is associated with decreased IL-10 and augmented chemokine production. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015, 308:L539-L549.
98. Wilson R., Cohen J.M., Jose R.J., de Vogel C., Baxendale H., Brown J.S. Protection against Streptococcus pneumoniae lung infection after nasopharyngeal colonization requires both humoral and cellular immune responses. Mucosal Immunol. 2014, 8(3):627-639.
99. Winter C., Herbold W., Maus R., Langer F., Briles D.E., Paton J.C., Welte T., Maus U.A. Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniae. J. Immunol. 2009, 182(8):4931-4937.
100. Witzenrath M., Pache F., Lorenz D., Koppe U., Gutbier B., Tabeling C., Reppe K., Meixenberger K., Dorhoi A., Ma J., Holmes A., Trendelenburg G., Heimesaat M.M., Bereswill S., van der Linden M., Tschopp J., Mitchell T.J., Suttorp N., Opitz B. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J. Immunol. 2011, 187(1):434-440.
101. Woehrl B., Brouwer M.C., Murr C., Heckenberg S.G., Baas F., Pfister H.W., Zwinderman A.H., Morgan B.P., Barnum S.R., van der Ende A., Koedel U., van de Beek D. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J. Clin. Investig. 2011, 121(10):3943-3953.
102. Wright A.K., Bangert M., Gritzfeld J.F., Ferreira D.M., Jambo K.C., Wright A.D., Collins A.M., Gordon S.B. Experimental human pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung. PLoS Pathog. 2013, 9(3):e1003274.
103. Wunderink R.G., Laterre P.F., Francois B., Perrotin D., Artigas A., Vidal L.O., Lobo S.M., Juan J.S., Hwang S.C., Dugernier T., LaRosa S., Wittebole X., Dhainaut J.F., Doig C., Mendelson M.H., Zwingelstein C., Su G., Opal S., Group C.T. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med. 2011, 183(11):1561-1568.
104. Wunderink R.G., Mandell L. Adjunctive therapy in community-acquired pneumonia. Semin. Respir. Crit. Care Med. 2012, 33(3):311-318.
105. Yamamoto N., Kawakami K., Kinjo Y., Miyagi K., Kinjo T., Uezu K., Nakasone C., Nakamatsu M., Saito A. Essential role for the p40 subunit of interleukin-12 in neutrophil-mediated early host defense against pulmonary infection with Streptococcus pneumoniae: involvement of interferon-gamma. Microb. Infect. 2004, 6(14):1241-1249.
106. Zhang Z., Clarke T.B., Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J. Clin. Investig. 2009, 119(7):1899-1909.
107. Zwijnenburg P.J., van der Poll T., Florquin S., Roord J.J., Van Furth A.M. IL-1 receptor type 1 gene-deficient mice demonstrate an impaired host defense against pneumococcal meningitis. J. Immunol. 2003, 170(9):4724-4730.
108. Zysk G., Bejo L., Schneider-Wald B.K., Nau R., Heinz H. Induction of necrosis and apoptosis of neutrophil granulocytes by Streptococcus pneumoniae. Clin. Exp. Immunol. 2000, 122(1):61-66.